Showing 491-500 of 854 results for "".
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Results of Phase 2 Study Demonstrate Safety and Efficacy of Galderma's Proprietary Liquid Toxinhttps://modernaesthetics.com/news/results-of-phase-2-study-demonstrate-safety-and-efficacy-of-galdermas-proprietary-liquid/2472827/Results of a Phase 2 study show Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines. Galderma is now poised to advance to Phase 3 testing of the liquid formulation of botulinum toxin type A for the treatment of glabellar lines. The tr
- Harper's Bazaar, NewBeauty Honor BTL HIFEM Deviceshttps://modernaesthetics.com/news/harpers-bazaar-newbeauty-honor-btl-hifem-devices/2471939/BTL has received two new accolades from NewBeauty and Harper's Bazaar
- New Cutera Survey Results Help Define Body Contouring Markethttps://modernaesthetics.com/news/new-cutera-survey-helps-define-body-contouring-market/2472026/One third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results we
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- Thermi Receives Health Canada Clearance to Market Thermi RF for Dermal Laxityhttps://modernaesthetics.com/news/there-receives-health-canada-clearance-to-market-thermi-rf-for-dermal-laxity/2472079/Therm
- Back by Popular Demand: Sciton's Bright Lights Big City BBL Tourhttps://modernaesthetics.com/news/back-by-popular-demand/2472107/Sciton. Inc.’s
- Revance, Mylan Partner to Develop Botox Biosimilarhttps://modernaesthetics.com/news/revance-mylan-partner-to-develop-botox-biosimilar/2472123/Mylan N.V. and